Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma-Reference-Cited by-同舟云学术

Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma

Published:2022-05-16 Issue:10 Volume:132 Page:
ISSN:1558-8238
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Takata Katsuyoshi,Chong Lauren C.,Ennishi Daisuke,Aoki Tomohiro^ORCID,Li Michael Yu,Thakur Avinash,Healy Shannon,Viganò Elena,Dao Tao,Kwon Daniel,Duns Gerben,Nielsen Julie S.,Ben-Neriah Susana,Tse Ethan,Hung Stacy S.,Boyle Merrill,Mun Sung Soo^ORCID,Bourne Christopher M.^ORCID,Woolcock Bruce,Telenius Adèle,Kishida Makoto,Rai Shinya,Zhang Allen W.,Bashashati Ali^ORCID,Saberi Saeed,D’Antonio Gianluca,Nelson Brad H.^ORCID,Shah Sohrab P.^ORCID,Hoodless Pamela A.,Melnick Ari M.^ORCID,Gascoyne Randy D.,Connors Joseph M.^ORCID,Scheinberg David A.,Béguelin Wendy^ORCID,Scott David W.^ORCID,Steidl Christian^ORCID

Funder

Terry Fox Research Institute

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/145343/files/pdf

Reference54 articles.

1. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

2. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

3. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte